Enveric Biosciences Inc. - news published 259 - readings 4.281

BACK
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders

CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced initiation of Good Laboratory Practice (GLP)-toxicology and safety pharmacology studi ...

Continue reading
18.10.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders - Form 8-K

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders Key preclinical milestone designed to establish safety profile and maximum tolerated dose for anticipated clinical trial of EB-373 CAMBRIDGE, Mass., October 18, 2023 - Enveric Biosciences (NASDAQ: ENVB) (&q ...

Continue reading
18.10.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit

Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit October 11, 2023 Presentations highlight research involving Enveric's EVM301 Series of non-hallucinogenic neuroplastogens and the company's lead product candidate, EB-373 CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company" ...

Continue reading
11.10.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit - Form 8-K

Enveric Biosciences Announces Two Poster Presentations at the 6 th Neuropsychiatric Drug Development Summit Presentations highlight research involving Enveric's EVM301 Series of non-hallucinogenic neuroplastogens and the company's lead product candidate, EB-373 CAMBRIDGE, Mass., October 11, 2023 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company&quo ...

Continue reading
11.10.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates - Form 8-K

Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates The Psybrary™ portfolio includes numerous unique, previously unreported molecules, which are protected by Enveric's expansive and growing intellectual property estate CAMBRIDGE, Mass., October 3, 2023 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric&quo ...

Continue reading
03.10.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates

Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates October 3, 2023 The Psybrary™ portfolio includes numerous unique, previously unreported molecules, which are protected by Enveric's expansive and growing intellectual property estate CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" ...

Continue reading
03.10.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Biotech firm receives patent for psilocybin-derived mental health therapeutics [Helio]

A Boston-area biotechnology firm announced it has received a patent titled "Carboxylated Psilocybin Derivatives and Methods of Using" for its EVM301 series of molecules to treat a range of mental health disorders. Full Article Attachments Original Link Original Document Permalink Disclaimer Enveric Biosciences Inc. published this content on 02 October 2023 and is sol ...

Continue reading
02.10.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry - Form 8-K

Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry Paper co-authored by Enveric researchers describes the discovery of a key cane toad enzyme and its application to the biosynthesis of novel indolethylamine-type drug candidates with potential use in psychi ...

Continue reading
27.09.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

U.S. approval for psychedelic drug MDMA nears after success in clinic [Labiotech]

The psychedelic drug MDMA edges closer towards FDA approval for the treatment of post-traumatic stress disorder (PTSD) in the U.S., after promising results of a trial were published. This comes after Australia became the first country to allow doctors to prescribe the drug to those struggling with mental health disorders like PTSD and depression. Full Story Attachments Origina ...

Continue reading
22.09.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here [Benzinga]

The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series EVM301 to its developer, Enveric Biosciences. Full Story Attachments Original Link Original Document Permalink Disclaimer Enveric Biosciences Inc. published this content on 22 September 2023 and ...

Continue reading
22.09.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates

CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,752,130, ...

Continue reading
20.09.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates - Form 8-K

Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates Claims to novel composition of matter and pharmaceutical drug formulations encompass EVM301 Series of drug candidates, targeting various difficult-to-treat mental health disorders by promoting neuroplasticity without induci ...

Continue reading
20.09.2023